Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent - PubMed (original) (raw)

Review

Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent

Anshul Shakya et al. Curr Drug Discov Technol. 2018.

Abstract

Background: The thiazolide nitazoxanide (NTZ) is a broad-spectrum antiinfective drug that adversely affects viability, growth, and proliferation of a range of extracellular and intracellular protozoan, helminths, anaerobic and microaerophilic bacteria, and viruses.

Method: Current review compiled the potential chemotherapeutic efficacy of NTZ against a variety of such disease-causing macro and/or micro-organisms as well as neoplastic cells, using various search engines viz. Web of Science, Scopus and Pub- Med up to February 2017.

Result: The most accepted anti-infective mechanism of NTZ involves impairment of the energy metabolism in anaerobic pathogens by inhibition of the pyruvate: ferredoxin/ flavodoxin oxidoreductase (PFOR). In parasitic-protozoan NTZ also induces lesions/voids in the cell membrane and depolarises the mitochondrial membrane along with the inhibition of quinone oxidoreductase NQO1, nitroreductase-1 and protein disulphide isomerase. NTZ also inhibits the glutathione-S-transferase (a major detoxifying enzyme) and modulates a gene (avr-14 gene) encoding for the alphatype subunit of glutamate-gated chloride ion channel present in the nematodes. Apart from well recognized non-competitive inhibition of the PFOR in anaerobic bacteria, NTZ also showed a variety of other antibacterial mechanisms viz. inhibits pyruvate dehydrogenase in the Escherichia coli, disrupts the membrane potential and pH homeostasis in the Mycobacterium tuberculosis, suppresses the chaperone/usher (CU) pathway of the gram-negative bacteria and stimulates host macrophage autophagy in the tubercular patients. NTZ also suppresses the viral replication by inhibiting maturation of the viral hemagglutinin and the viral transcription factor immediate early 2 (IE2) as well as by activating the eukaryotic translation initiation factor 2α (an antiviral intracellular protein). Additionally, NTZ expresses inhibitory effect on the tumour cell progression by modulating drug detoxification (glutathione-S-transferase P1), unfolded protein response, autophagy, anti-cytokines activities and c-Myc inhibition.

Conclusion: These potentially versatile molecular interactions of NTZ within invading pathogen(s) and immunomodulatory efficacy over the hosts, justify the multifunctional chemotherapeutic significance of this chemical agent.

Keywords: Antiviral; anthelminthic; antibacterial; anticancer; antiprotozoal; thiazolide..

PubMed Disclaimer

Cited by

The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan.
Li W, Chen S, Lang J, Luo J, Chen J, Zhang L, Sun Z, Dong D. Li W, et al. Acta Pharm Sin B. 2024 Jul;14(7):3266-3280. doi: 10.1016/j.apsb.2024.03.031. Epub 2024 Mar 28. Acta Pharm Sin B. 2024. PMID: 39027239 Free PMC article.
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Iacobino A, Giannoni F, Pardini M, Piccaro G, Fattorini L. Iacobino A, et al. Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00273-19. doi: 10.1128/AAC.00273-19. Print 2019 Jul. Antimicrob Agents Chemother. 2019. PMID: 31010861 Free PMC article.
Transcriptional Differential Analysis of Nitazoxanide-Mediated Anticanine Parvovirus Effect in F81 Cells.
Su X, Zhou H, Han Z, Xu F, Xiao B, Zhang J, Qi Q, Lin L, Zhang H, Li S, Yang B. Su X, et al. Viruses. 2024 Feb 12;16(2):282. doi: 10.3390/v16020282. Viruses. 2024. PMID: 38400057 Free PMC article.
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.
Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Beigel JH, et al. Antiviral Res. 2019 Jul;167:45-67. doi: 10.1016/j.antiviral.2019.04.006. Epub 2019 Apr 8. Antiviral Res. 2019. PMID: 30974127 Free PMC article. Review.
Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis.
Li CH, Lü ZR, Zhao ZD, Wang XY, Leng HJ, Niu Y, Wang MP. Li CH, et al. Front Pharmacol. 2021 Dec 9;12:781640. doi: 10.3389/fphar.2021.781640. eCollection 2021. Front Pharmacol. 2021. PMID: 34955850 Free PMC article.

Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent - PubMed (original) (raw)